Next Article in Journal
Inhibitors of BRD4 Protein from a Marine-Derived Fungus Alternaria sp. NH-F6
Next Article in Special Issue
Characterization and Potential Antitumor Activity of Polysaccharide from Gracilariopsis lemaneiformis
Previous Article in Journal
Krill Oil-In-Water Emulsion Protects against Lipopolysaccharide-Induced Proinflammatory Activation of Macrophages In Vitro
Article Menu
Issue 3 (March) cover image

Export Article

Open AccessFeature PaperArticle
Mar. Drugs 2017, 15(3), 75; doi:10.3390/md15030075

FUSION-Guided Hypothesis Development Leads to the Identification of N6,N6-Dimethyladenosine, a Marine-Derived AKT Pathway Inhibitor

1
Department of Cell Biology, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
2
Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX 75235, USA
3
Cell & Molecular Biology Department, St. Jude Children’s Research Hospital, Memphis, TN 38105, USA
*
Authors to whom correspondence should be addressed.
Academic Editors: Yu-Dong Zhou, Dale G. Nagle and Paul Long
Received: 7 December 2016 / Revised: 2 March 2017 / Accepted: 11 March 2017 / Published: 15 March 2017
(This article belongs to the Special Issue Marine Drugs as Antitumour Agents 2017)
View Full-Text   |   Download PDF [2182 KB, uploaded 15 March 2017]   |  

Abstract

Chemicals found in nature have evolved over geological time scales to productively interact with biological molecules, and thus represent an effective resource for pharmaceutical development. Marine-derived bacteria are rich sources of chemically diverse, bioactive secondary metabolites, but harnessing this diversity for biomedical benefit is limited by challenges associated with natural product purification and determination of biochemical mechanism. Using Functional Signature Ontology (FUSION), we report the parallel isolation and characterization of a marine-derived natural product, N6,N6-dimethyladenosine, that robustly inhibits AKT signaling in a variety of non-small cell lung cancer cell lines. Upon validation of the elucidated structure by comparison with a commercially available sample, experiments were initiated to understand the small molecule’s breadth of effect in a biological setting. One such experiment, a reverse phase protein array (RPPA) analysis of >50 kinases, indicated a specific cellular response to treatment. In all, leveraging the FUSION platform allowed for the rapid generation and validation of a biological mechanism of action hypothesis for an unknown natural product and permitted accelerated purification of the bioactive component from a chemically complex fraction. View Full-Text
Keywords: dimethyladenosine; AKT; functional signature ontology dimethyladenosine; AKT; functional signature ontology
Figures

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Supplementary materials

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Vaden, R.M.; Oswald, N.W.; Potts, M.B.; MacMillan, J.B.; White, M.A. FUSION-Guided Hypothesis Development Leads to the Identification of N6,N6-Dimethyladenosine, a Marine-Derived AKT Pathway Inhibitor. Mar. Drugs 2017, 15, 75.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Mar. Drugs EISSN 1660-3397 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top